MK-677 vs CJC-1295 compared: how the oral ghrelin agonist differs from the injectable GHRH analog in half-life, dosing, side effects, and legal status.
MK-677 and CJC-1295 both raise growth hormone (GH) and IGF-1, but they work through completely different receptors. MK-677 is an oral, non-peptide ghrelin receptor agonist, while CJC-1295 is an injectable peptide that acts as a growth hormone-releasing hormone (GHRH) analog. Neither compound is FDA-approved for human use in the United States, and both are sold as research chemicals rather than medicines.
What Is MK-677 (Ibutamoren)?
MK-677, also known as ibutamoren, is a small non-peptide molecule taken by mouth. It binds to ghrelin receptors in the brain and pituitary, which triggers GH release and raises IGF-1 levels. Because it is orally active, MK-677 does not require injection.
Its half-life is roughly 24 hours, so one dose keeps GH and IGF-1 elevated for most of the day. That long window is the main reason MK-677 is described as a steady, always-on GH secretagogue rather than a pulsatile one.
Reported effects in informal research settings include a strong increase in appetite, water retention, and mild lethargy in some users.
What Is CJC-1295?
CJC-1295 is a modified fragment of GRF(1-29), the active portion of growth hormone-releasing hormone. It is given by subcutaneous injection and binds to pituitary GHRH receptors, prompting the pituitary to release GH in a pulse.
The compound exists in two versions: CJC-1295 with DAC (drug affinity complex) and CJC-1295 without DAC, often called mod GRF(1-29). Anyone researching cjc-1295 dac vs no dac is really deciding between a long-acting peptide and a short-acting one.
CJC-1295 with DAC has a half-life of about 6 to 8 days, while CJC-1295 without DAC lasts roughly 30 minutes. That single difference drives dosing frequency, injection timing, and how natural the resulting GH pulse looks.
MK-677 vs CJC-1295: Side-by-Side Comparison
| Feature | MK-677 (Ibutamoren) | CJC-1295 |
|---|---|---|
| Route | Oral (capsule or liquid) | Subcutaneous injection |
| Class | Ghrelin receptor agonist (non-peptide) | GHRH analog (peptide) |
| Half-life | About 24 hours | About 30 minutes (no DAC); 6-8 days (with DAC) |
| GH pattern | Steady, prolonged elevation | Sharp pulse (no DAC) or sustained elevation (with DAC) |
| Appetite effect | Strong increase | Minimal |
| Typical research dose | 10-25 mg once daily | 1-2 mcg/kg 1-3x daily (no DAC); about 2 mg weekly (with DAC) |
| FDA status | Not approved for human use | Not approved for human use |
Those dose figures come from research literature and vendor labeling, not approved medical dosing. CJC-1295 has no approved human dose, and none of these numbers should be treated as a prescription.
Dosing, Timing, and Day-to-Day Differences
MK-677 is usually taken once daily, often before bed, because it does not depend on injection timing. Hunger climbs within hours, and users frequently report deeper sleep along with puffiness in the face and ankles.
CJC-1295 without DAC is injected more frequently and produces a short GH pulse that mimics natural secretion. CJC-1295 with DAC is injected far less often but keeps GH elevated continuously, which is closer to the MK-677 pattern than most people expect.
If the goal is IGF-1 elevation, it helps to know that some compounds bypass GH entirely. A comparison such as cjc 1295 vs igf 1 lr3 covers that distinction, since IGF-1 LR3 acts downstream of the pituitary.
Can You Stack MK-677 With CJC-1295?
Some researchers combine them because MK-677 targets ghrelin receptors while CJC-1295 targets GHRH receptors. Activating two separate pathways can produce a larger GH release than either compound alone.
That same overlap raises the risk of side effects. Water retention, elevated fasting blood sugar, joint pain, and lethargy can all compound when two GH-raising agents are used together.
People weighing cjc-1295 vs ipamorelin are usually choosing between a GHRH analog and a ghrelin-mimicking peptide, which is the same receptor class MK-677 belongs to. That is why a CJC-1295 and ipamorelin stack and an MK-677 and CJC-1295 stack are often discussed as competing ways to chase the same outcome.
Alternatives and Related Comparisons
MK-677 and CJC-1295 are not the only options, and the alternatives differ in duration, cost, and regulatory status.
- Shorter GHRH analogs: sermorelin is an older GHRH analog with a half-life measured in minutes, so it is dosed more often and produces a briefer pulse. Many people reading cjc-1295 vs sermorelin comparisons want a longer-acting GHRH signal.
- Fat-loss compounds: MK-677 and CJC-1295 are used to raise GH, not to target fat directly, so if fat reduction is the objective a comparison like aod 9604 vs cjc-1295 ipamorelin answers a different question entirely.
Side Effects and Safety Considerations
Both compounds carry real risks, and neither has a safety profile established by large human trials.
- MK-677: increased appetite, water retention, numbness or tingling in the hands, morning grogginess, and rising fasting blood glucose or insulin resistance with prolonged use.
- CJC-1295: injection-site reactions, flushing, headache, and possible pituitary desensitization with continuous high-dose use.
Chronically elevated GH and IGF-1 are associated with health risks that should not be ignored, including effects on glucose metabolism and tissue growth. Anyone considering MK-677 or CJC-1295 should discuss it with a healthcare professional instead of self-experimenting.
Legal Status and Sourcing
MK-677 has never been approved for human use by the FDA or any comparable regulator. CJC-1295 also has no approved human indication, although the related GHRH analog tesamorelin is FDA-approved for HIV-associated lipodystrophy.
Both MK-677 and CJC-1295 are widely sold as research-use-only products, a label that means they are not intended for human consumption. Purity and actual content vary between vendors, and independent third-party testing is often the only way to know what a vial or capsule contains.
Bottom Line: Which One Fits Your Goal?
There is no single winner here, because the two compounds solve different problems.
- Choose MK-677 if oral dosing, once-a-day convenience, and appetite stimulation matter most.
- Choose CJC-1295 if you want an injectable GHRH analog whose duration can be tuned with or without DAC.
- Consider neither if you are not prepared to monitor blood glucose, blood pressure, and IGF-1, or if you have no clinician to guide you.
MK-677 is not a substitute for CJC-1295, and CJC-1295 is not simply a stronger version of MK-677. They act on separate receptors, produce different GH patterns, and carry overlapping but distinct risks.
Frequently Asked Questions
Is MK-677 stronger than CJC-1295?
The two are not directly comparable because they act on different receptors. MK-677 keeps GH elevated around the clock thanks to its roughly 24-hour half-life, while CJC-1295 without DAC produces a short, sharp pulse that clears within about 30 minutes. Which one raises GH more depends on the dose, the formulation, and the individual, and neither is FDA-approved for human use.
Can you stack MK-677 and CJC-1295 together?
Some researchers combine them because MK-677 activates ghrelin receptors while CJC-1295 activates GHRH receptors, and hitting both pathways can increase GH release. The tradeoff is a higher chance of water retention, elevated fasting blood glucose, joint discomfort, and lethargy. This combination is not low risk and should be discussed with a physician.
Does MK-677 need to be injected?
No. MK-677 is orally active and is typically taken as a capsule, tablet, or liquid, usually once per day. CJC-1295 must be injected subcutaneously because it is a peptide that would be broken down in the digestive tract.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.